SuperworthOvid Therapeutics PE ratio OVID
Share price divided by earnings per share over the last twelve months, since 2016.
- Today, Oct 23, 2026
- n/m
- losses over the last year
- Earnings per share, 12 months
- −$0.25
- to Jun 30, 2026
- Share price
- $2.16
- Oct 23, 2026
- Peer median
- 11.5×
Ovid Therapeutics has no meaningful PE ratio today: it lost $0.25 a share over the last twelve months, and a PE needs earnings.
It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.
Earnings per share over time
A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.25 | n/a |
| FY2024 | −$0.38 | n/a |
| FY2023 | −$0.75 | n/a |
| FY2022 | −$0.77 | −144% |
| FY2021 | $1.76 | n/a |
| FY2020 | −$1.40 | n/a |
| FY2019 | −$1.58 | n/a |
| FY2018 | −$2.12 | n/a |
| FY2017 | −$4.88 | n/a |
| FY2016 | −$2.28 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.08 | n/a | −$0.25 | |
| Q1 FY26 | −$0.12 | n/a | −$0.23 | |
| Q4 FY25 | $0.12 | n/a | −$0.25 | |
| Q3 FY25 | −$0.17 | n/a | −$0.50 | |
| Q2 FY25 | −$0.06 | −150% | −$0.53 | |
| Q1 FY25 | −$0.14 | n/a | −$0.35 | |
| Q4 FY24 | −$0.13 | n/a | −$0.38 | |
| Q3 FY24 | −$0.20 | n/a | −$0.47 | |
| Q2 FY24 | $0.12 | n/a | −$0.43 | |
| Q1 FY24 | −$0.17 | n/a | −$0.73 | |
| Q4 FY23 | −$0.22 | n/a | −$0.75 | |
| Q3 FY23 | −$0.16 | n/a | −$0.69 |
Against its peers
Companies in Drug Manufacturers - General nearest Ovid Therapeutics' size, closest first, today.
| Company | PE ratio |
|---|---|
| OVIDOvid Therapeutics | n/m |
| ARVNArvinas | 45.6× |
| PBYIPuma Biotechnology | 21.2× |
| IRWDIronwood Pharmaceuticals | 4.5× |
| ZVRAZevra Therapeutics | 10.5× |
| CRMDCorMedix | 3.7× |
| COLLCollegium Pharmaceutical | 18.5× |
| ABUSArbutus Biopharma | 5.4× |
| NATRNatures Sunshine Products | 12.0× |
| AMPHAmphastar Pharmaceuticals | 14.8× |
| OMEROmeros | 10.9× |
| Peer median | 11.5× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Ovid Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.